A detailed history of Citigroup Inc transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Citigroup Inc holds 34,566 shares of CABA stock, worth $94,710. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,566
Previous 22,894 50.98%
Holding current value
$94,710
Previous $171,000 4.68%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.94 - $8.24 $45,987 - $96,177
11,672 Added 50.98%
34,566 $163,000
Q2 2024

Aug 12, 2024

SELL
$7.22 - $18.82 $2.01 Million - $5.25 Million
-278,992 Reduced 92.42%
22,894 $171,000
Q1 2024

May 10, 2024

BUY
$16.79 - $25.38 $3.62 Million - $5.47 Million
215,340 Added 248.82%
301,886 $5.15 Million
Q4 2023

Feb 09, 2024

BUY
$12.21 - $23.36 $449,950 - $860,839
36,851 Added 74.15%
86,546 $1.96 Million
Q3 2023

Nov 09, 2023

BUY
$11.84 - $18.65 $498,203 - $784,754
42,078 Added 552.42%
49,695 $756,000
Q2 2023

Aug 10, 2023

SELL
$7.65 - $13.95 $291,732 - $531,983
-38,135 Reduced 83.35%
7,617 $98,000
Q1 2023

May 11, 2023

BUY
$7.08 - $12.62 $323,924 - $577,390
45,752 New
45,752 $378,000
Q3 2022

Nov 10, 2022

SELL
$0.63 - $2.05 $61 - $198
-97 Reduced 22.2%
340 $0
Q2 2022

Aug 10, 2022

SELL
$0.99 - $2.11 $1,345 - $2,867
-1,359 Reduced 75.67%
437 $0
Q1 2022

May 12, 2022

SELL
$1.68 - $3.92 $1,120 - $2,614
-667 Reduced 27.08%
1,796 $4,000
Q4 2021

Feb 10, 2022

BUY
$3.36 - $14.64 $1,565 - $6,822
466 Added 23.34%
2,463 $9,000
Q3 2021

Nov 10, 2021

BUY
$7.0 - $12.5 $13,979 - $24,962
1,997 New
1,997 $24,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $79.5M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.